CS-7017 + Paclitaxel
Phase 1/2Terminated 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anaplastic Thyroid Cancer
Conditions
Anaplastic Thyroid Cancer
Trial Timeline
Jan 1, 2008 → Dec 1, 2011
NCT ID
NCT00603941About CS-7017 + Paclitaxel
CS-7017 + Paclitaxel is a phase 1/2 stage product being developed by Daiichi Sankyo for Anaplastic Thyroid Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT00603941. Target conditions include Anaplastic Thyroid Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00603941 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Anaplastic Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | 52 |
| Lenvatinib 24 mg | Eisai | Phase 2 | 52 |
| Lenvatinib + Nivolumab | Ono Pharmaceutical | Phase 2 | 52 |
| durvalumab + tremelimumab | AstraZeneca | Phase 1 | 33 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| LDK378 + AUY922 | Novartis | Phase 1 | 33 |
| ceritinib | Novartis | Pre-clinical | 23 |
| LDK378 | Novartis | Phase 1 | 33 |
| Ceritinib | Novartis | Phase 2 | 52 |
| Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim | Novartis | Phase 1 | 33 |
| dabrafenib/trametinib | Novartis | Phase 2 | 52 |
| Trametinib + Paclitaxel | Novartis | Phase 1 | 33 |
| Alectinib + Crizotinib | Roche | Phase 3 | 77 |
| Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Crizotinib (PF-02341066) | Pfizer | Phase 2 | 51 |
| Lorlatinib | Pfizer | Phase 2 | 51 |
| Crizotinib | Pfizer | Phase 1/2 | 40 |
| Cemiplimab + XL092 | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Etirinotecan pegol | Nektar Therapeutics | Phase 2 | 47 |
| Bevacizumab | Novocure | Phase 2 | 47 |